Lab to Impact Health Module: From Discovery to Diagnostics, Navigating Biomarker Commercialization

Wednesday, February 19 | 12 – 1 p.m. ET | Virtual 

Interested in understanding the journey from biomarker discovery to real-world healthcare applications? Researchers and innovators are invited to this insightful discussion on navigating the path from discovery to commercial success in the biomarker and diagnostics space. 

Industry leaders and successful entrepreneurs will share practical insights on identifying commercially viable biomarkers, early-stage validation, test development, regulatory pathways, and integration into clinical practice. Whether you’re considering commercialization or actively developing diagnostic solutions, this panel offers valuable perspectives on turning promising research into market-ready products. 

Moderated by Iris Bica, a Business Development and Licensing Associate for the Center of Technology Licensing at Weill Cornell Medicine, the panel will feature:  

• Dan Klass, Senior Director of Emerging Technologies, Freenome  

• Marieke Spaan, Senior Director Corporate Development, SkylineDx  

• Daniel Lunz, CEO & Co-Founder, Previse 

RSVP here